552.4K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 138,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,000 | 194,506 | - | 0 | Series A Common Stock | |
| Thierry Chauche | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 17,000 | 17,000 | - | 0 | Series A Common Stock | |
| Thierry Chauche | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 69,000 | 69,000 | - | - | Stock Option (Right to Buy) | |
| Eduardo Bruno Martins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 138,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
| Eduardo Bruno Martins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,000 | 115,213 | - | 0 | Series A Common Stock | |
| David Happel | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 116,000 | 755,200 | - | 0 | Series A Common Stock | |
| David Happel | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 472,000 | 472,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 113,895 | 113,895 | - | - | Stock Option (Right to Buy) | |
| Anne M. Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 113,895 | 113,895 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 3.17 per share. | 23 Jul 2024 | 23,625 | 118,693 | - | 3.2 | 74,830 | Series A Common Stock |
| George Kemble | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 3.10 per share. | 19 Jul 2024 | 14,062 | 142,318 | - | 3.1 | 43,605 | Series A Common Stock |
| Eduardo Bruno Martins | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.10 per share. | 19 Jul 2024 | 8,357 | 81,213 | - | 3.1 | 25,910 | Series A Common Stock |
| Elizabeth Rozek | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 3.10 per share. | 19 Jul 2024 | 10,914 | 160,506 | - | 3.1 | 33,830 | Series A Common Stock |
| Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 51,459 | 51,459 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Grammer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 51,459 | 51,459 | - | - | Stock Option (Right to Buy) | |
| Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 9,279 | 9,279 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Walbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 9,279 | 9,279 | - | - | Stock Option (Right to Buy) | |
| Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 51,459 | 51,459 | - | - | Stock Option (Right to Buy) | |
| Thierry Chauche | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 587,181 | 587,181 | - | - | Stock Option (Right to Buy) | |
| Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 73,014 | 73,014 | - | - | Stock Option (Right to Buy) | |
| Timothy P. Walbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 73,014 | 73,014 | - | - | Stock Option (Right to Buy) | |
| David Happel | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 5.27 per share. | 26 Mar 2024 | 12,100 | 639,200 | - | 5.3 | 63,731 | Series A Common Stock |
| Happel David | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 4.10 per share. | 07 Dec 2023 | 1,600 | 627,100 | - | 4.1 | 6,560 | Series A Common Stock |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 3,179 | 3,179 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 3,349 | 3,349 | - | - | Stock Option (Right to Buy) | |
| Jinzi Jason Wu | Director | 18 Jul 2023 | 1,654,701 | 1,654,701 | - | - | Series A Common Stock | ||
| Jinzi Jason Wu | Director | 18 Jul 2023 | 108,471,634 | 0 | - | - | Series E Preferred Stock | ||
| Jinzi Jason Wu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 23,216 | - | - | Stock Option (Right to Buy) | |
| Jinzi Jason Wu | Director | 18 Jul 2023 | 23,041,474 | 0 | - | - | Series F Preferred Stock | ||
| Jinzi Jason Wu | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 0 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 242,142 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Rozek | General Counsel and CCO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 0 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 21,173 | 21,173 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 5,630 | 0 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 5,630 | 5,630 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 3,179 | 0 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | 18 Jul 2023 | 327,309 | 0 | - | - | Series E Preferred Stock | ||
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 7,147 | 0 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 7,147 | 7,147 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 26,352 | 0 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 26,352 | 26,352 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 367,824 | 0 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 367,824 | 367,824 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 46,432 | 0 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 46,432 | 46,432 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 526,332 | 0 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 526,332 | 526,332 | - | - | Stock Option (Right to Buy) | |
| George Kemble | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 21,173 | 0 | - | - | Stock Option (Right to Buy) | |
| Beth C. Seidenberg | Director | 18 Jul 2023 | 6,103,580 | 0 | - | - | Series D Preferred Stock | ||
| Dennis Hom | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 136,846 | 136,846 | - | - | Stock Option (Right to Buy) | |
| Dennis Hom | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 111,438 | 111,438 | - | - | Stock Option (Right to Buy) | |
| Dennis Hom | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 9,286 | 0 | - | - | Stock Option (Right to Buy) | |
| Dennis Hom | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 111,438 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard J. Rodgers | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 1,976 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 23,216 | - | - | Stock Option (Right to Buy) | |
| Richard J. Rodgers | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 1,976 | 1,976 | - | - | Stock Option (Right to Buy) | |
| Richard J. Rodgers | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard J. Rodgers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 23,839 | - | - | Stock Option (Right to Buy) | |
| Beth C. Seidenberg | Director | 18 Jul 2023 | 8,596,590 | 0 | - | - | Series B-1 Preferred Stock | ||
| Beth C. Seidenberg | Director | 18 Jul 2023 | 8,596,589 | 0 | - | - | Series C Preferred Stock | ||
| Dennis Hom | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 136,846 | 0 | - | - | Stock Option (Right to Buy) | |
| Beth C. Seidenberg | Director | 18 Jul 2023 | 6,737,254 | 0 | - | - | Series E Preferred Stock | ||
| Beth C. Seidenberg | Director | 18 Jul 2023 | 103,127,234 | 0 | - | - | Series E Preferred Stock | ||
| Beth C. Seidenberg | Director | 18 Jul 2023 | 20,430,107 | 0 | - | - | Series F Preferred Stock | ||
| Beth C. Seidenberg | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 0 | - | - | Stock Option (Right to Buy) | |
| Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 23,216 | - | - | Stock Option (Right to Buy) | |
| Beth C. Seidenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 38,763 | 38,763 | - | - | Series A Common Stock | |
| Beth C. Seidenberg | Director | 18 Jul 2023 | 1,860,712 | 1,899,475 | - | - | Series A Common Stock | ||
| Beth C. Seidenberg | Director | 18 Jul 2023 | 84,768 | 84,768 | - | - | Series A Common Stock | ||
| Beth C. Seidenberg | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 18 Jul 2023 | 46,875 | 46,875 | - | 16 | 750,000 | Series A Common Stock |
| Beth C. Seidenberg | Director | 18 Jul 2023 | 539,006 | 0 | - | - | Series A Preferred Stock | ||
| Beth C. Seidenberg | Director | 18 Jul 2023 | 493,370 | 0 | - | - | Series B Preferred Stock | ||
| Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 2,086 | 2,086 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 23,839 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 0 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 23,216 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 0 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 144 | 144 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 144 | 0 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 8,677 | 0 | - | - | Common Stock | |
| Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 8,677 | 8,677 | - | - | Series A Common Stock | |
| Merdad V. Parsey | Director | 18 Jul 2023 | 4,117 | 12,794 | - | - | Series A Common Stock | ||
| Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 2,086 | 0 | - | - | Stock Option (Right to Buy) | |
| Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 3,349 | 0 | - | - | Stock Option (Right to Buy) | |
| Beth C. Seidenberg | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 38,763 | 0 | - | - | Common Stock | |
| Eduardo Bruno Martins | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 198,132 | 0 | - | - | Stock Option (Right to Buy) | |
| Eduardo Bruno Martins | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 44,009 | 0 | - | - | Stock Option (Right to Buy) | |
| Eduardo Bruno Martins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 44,009 | 44,009 | - | - | Stock Option (Right to Buy) | |
| Eduardo Bruno Martins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 198,132 | 198,132 | - | - | Stock Option (Right to Buy) | |
| David Happel | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 1,011,826 | 0 | - | - | Stock Option (Right to Buy) | |
| David Happel | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 1,011,826 | 1,011,826 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Grammer | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 49,533 | 0 | - | - | Stock Option (Right to Buy) | |
| Elizabeth Grammer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 49,533 | 49,533 | - | - | Stock Option (Right to Buy) | |
| Anthony Rimac | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 0 | - | - | Stock Option (Right to Buy) | |
| Anthony Rimac | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 242,142 | - | - | Stock Option (Right to Buy) | |
| Dennis Hom | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 9,286 | 9,286 | - | - | Stock Option (Right to Buy) |